Senores Pharmaceuticals Ltd share price softened by 4.79% to Rs 1252.4 after the company's net profit declined by 16.96% to Rs 30.45 crore, while revenue from operations improved marginally 2.87% to Rs 180.21 crore in Q2FY26 over Q1FY26.

The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.97 lakh crore, gaining 4.13%. It has eased by 1.18% over last one week and eased lower by 1.03% in last one month while the market capitalization of Senores Pharmaceuticals Ltd has slipped by 2.31% and 10.26% in the same period respectively.

Profit before tax (PBT) of Senores Pharmaceuticals Ltd stood at Rs 39.46 crore in Q2 FY26, expanding by 48.96% year-on-year, and plunging by 16.75% quarter-on-quarter. EBITDA came in at Rs 51 crore, surging by 155.52% YoY and jumping 70.86% sequentially.

Total expenses slightly declined by 0.45% to Rs 136.39 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 31.15 crore, rising 15.16% YoY, while employee benefits expense was at Rs 29.91 crore, seeing a marginal contraction of 1.35% YoY.

For the TTM ended FY26, revenue from operations witnessed a strong growth of 85.65% to Rs 398.25 crore, while net profit jumped 78.36% to Rs 58.34 crore, compared to previous TTM. EBITDA surged by 4460% to Rs 70.44 crore, and PBT witnessed a strong rise of 182.85% to Rs 70.57 crore compared to previous TTM.

The company's consolidated net cash flow from operating activities stood at Rs 45.92 crore in FY26, as against Rs 25.7 crore in FY25.

Senores Pharmaceuticals Ltd soared by 72.67% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 12.46% during the same period.